HSCS
HeartSciences Inc.
There isn't enough reported data to score HSCS yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
HSCS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
HSCS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HSCS PE Valuation
HSCS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HSCS Forward outlook
There aren't enough analyst estimates for HSCS to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HSCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.76 | +$5.52 |
| Q2 2026 | -$3.48 | +$5.86 |
| Q1 2024 | -$46.00 | +$84.03 |
| Q4 2023 | -$59.00 | +$92.30 |
| Q3 2023 | -$65.00 | +$95.53 |
| Q2 2023 | -$80.00 | +$67.67 |
| Q1 2023 | -$130.03 | -$20.69 |
HSCS is still losing money, but far less than before: $2.76 per share over the past year, against $160.53 at its worst in mid-2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over HSCS on earnings quality, reporting a profit while its opponent remains loss making.
HSCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1K | +11% |
| Q1 2024 | $14.7K | +654% |
| Q1 2023 | $2K | -29% |
| Q3 2022 | $3.2K | -57% |
| Q2 2022 | $4.1K | -72% |
HSCS's revenue is recovering but still below its 2021 peak: $2,100 last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139957% | -41319 points |
| Q4 2025 | -85713% | N/A |
| Q3 2025 | -98638% | N/A |
| Q1 2024 | -10377% | +56767 points |
| Q4 2023 | -40255% | N/A |
| Q1 2023 | -67144% | -26987 points |
| Q3 2022 | -44691% | -35679 points |
| Q2 2022 | -47670% | -42410 points |
HSCS's operating margin was −139957% last quarter, down 99702 points from the same quarter a year ago, near the bottom of its range since 2021.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over HSCS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over HSCS on profitability, with a higher operating margin.
HSCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | +$634.5K |
| Q2 2026 | -$1.7M | -$85.9K |
| Q1 2026 | -$1.5M | +$167K |
| Q3 2025 | -$2M | +$65.4K |
| Q2 2025 | -$1.6M | -$5.5K |
| Q1 2025 | -$1.6M | +$530.1K |
| Q3 2024 | -$2M | -$609.5K |
| Q2 2024 | -$1.6M | +$284.1K |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with HSCS at down 11%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
HSCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +507K shares |
| 1 year | +272% | +2.7M shares |
| 3 years | +6399% | +3.6M shares |
HSCS has 4M diluted shares, up 272% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over HSCS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
HSCS Net Leverage
HSCS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HSCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.7 | Neutral |
HSCS's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
HSCS PE vs Healthcare Sector
HSCS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HSCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.35 | 33% below |
| 20 week MA | $3.09 | 27% below |
| 50 week MA | $2.73 | 17% below |
| 100 week MA | $3.07 | 26% below |
| 200 week MA | $24.3 | 91% below |
HSCS is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over HSCS on trend strength, trading above more of its moving averages.
HSCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $208.0 | $89.0 | -57% |
| 2023 | $89.0 | $17.1 | -81% |
| 2024 | $17.1 | $3.81 | -78% |
| 2025 | $3.81 | $2.85 | -25% |
| 2026 YTD | $2.85 | $2.26 | -21% |
HSCS has finished every year since 2022 lower, and it's down 21% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over HSCS on returns for 2026, with the stronger performance.